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subscale for paediatric CFS/ME:
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Abstract
Background: Defining the minimally clinically important difference (MCID) is important for the design and analysis of
clinical trials and ensures that findings are clinically meaningful. Studies in adult populations have investigated the
MCID of The Short Form 36 physical function sub-scale (SF-36-PFS). However, to our knowledge no studies have
defined the MCID of the SF-36-PFS in a paediatric population. We aimed to triangulate findings from distribution,
anchor and qualitative methods to identify the MCID of the SF-36-PFS for children and adolescents with CFS/ME.
Methods: Quantitative methods: We analysed routinely-collected data from a specialist paediatric CFS/ME service in South-
West England using: 1) the anchor method, based on Clinical Global Impression (CGI) outcomes at 6 months’ follow-up; 2)
the distribution method, based on the standard deviation of baseline SF-36-PFS scores.
Qualitative methods: Young people (aged 12–17 years) and parents were asked to complete the SF-36-PFS, marking each
question twice: once for where they would currently rate themselves/their child and a second time to show what they felt
would be the smallest amount of change for them/their child to feel treatment had made a difference. Semi-structured
interviews were designed to explore what factors were deemed important to patients and to what extent an improvement
was considered satisfactory. We thematically analysed qualitative interviews from 21 children and their parents.
Results: Quantitative results: Six-month follow-up data were available for 198 children with a mean age of 14 years. Most
were female (74%, 146/198) and 95% gave their ethnicity as “White British”.
Half the standard deviation of the baseline SF-36-PFS scores was 11.0. “A little better” on the CGI equated to a mean
difference on the SF-36-PFS from baseline to 6-month follow-up of 9.0.
Qualitative results: Twenty-one children with CFS/ME participated: 16 females (76.2%) with a mean age of 14.4 years. Twenty
mothers and two fathers were also interviewed.
The median minimal improvement in the SF-36-PFS was 10. Participants indicated that small changes in physical function
can lead to important improvements in valued social and family function. Patients and parents were positive about
improvement even in the presence of persisting symptoms.
Triangulation: The MCID based on the mean score from the three methods was 10.
Conclusions: Converging evidence indicates future studies in paediatric CFS/ME should use an MCID of 10 on the SF-36-PFS.
Keywords: Minimal clinically important difference (MCID), Paediatric, Chronic fatigue syndrome, Myalgic encephalomyelitis,
CFS/ME
* Correspondence: amberly.brigden@bristol.ac.uk
1Population Health Sciences, Centre for Academic Child Health, Bristol
Medical School, University of Bristol, 1-5 Whiteladies Road, Bristol BS8 1NU,
UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Brigden et al. Health and Quality of Life Outcomes          (2018) 16:202 
https://doi.org/10.1186/s12955-018-1028-2
Background
The Minimal Clinically Important Difference (MCID) is
defined as “the smallest difference in score in the domain of
interest which patients perceive as beneficial and which
would mandate, in the absence of troublesome side effects
and excessive cost, a change in the patient’s management”
[1]. The MCID is used in trials to calculate sample size and
interpret results [2]. Distribution methods compare the
change in scores on the outcomes measure to a measure of
variability, including the standard error of measurement
(SEM), the standard deviation (SD), the effect size, or the
minimum detectable change (MDC) [3]. Whilst a variety of
effect sizes and SEMs can be used, calculating the MCID
using 0.5 SD is popular and it has been show to corresponds
to the MCID across a variety of studies [4]. However,
distribution methods may not be clinically relevant to pa-
tients [5] and will vary on the sample size that the SD is
based on. Alternative methods to determining a more clinic-
ally relevant MCID are the anchor method and using qualita-
tive methodology. The anchor method correlates the change
on an outcome measure with prospectively collected change
data on a global assessment scale [6] – i.e. those who defined
the difference as “better” are compared against those who
stated they were “unchanged”. However, there are limitations
of the anchor method. The decision about where the cut-off
should be on the anchor scale is often arbitrary [7] and argu-
ably, a global assessment may not always be valid [8]. Quali-
tative methods enable richer exploration of the patient’s
perspective of minimal level of change, but can lack the pre-
cision needed to determine a numerical marker of MCID [8].
Table 1 summarise the advantages and disadvantages of these
methods. Because of the strengths and limitations of each
method, triangulating multiple methods provides a solution
to defining a precise and clinically meaningful MCID [8].
The Short Form 36 (SF-36) [9] is a widely used general
health-status measure. The SF-36 physical function sub-scale
(SF-36-PFS) consists of ten items and is used to measure
change in disability in many chronic illnesses including
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/
ME) [10–13]. An MCID defined as 0.3/0.5 SD of the
SF-36-PFS, typically equating to 8 to 10 points has been used
in adult and paediatric CFS/ME [14–17], but it is unclear if
this is appropriate and clinically relevant for patients. In
other conditions, the Delphi method has suggested an MCID
of 10 for asthma and heart disease [18], and 5 for Chronic
Obstructive Pulmonary Disease in adults [18]. Anchor and
distribution methods have identified the MCID as ranging
from 3.25–20.40 for hip and knee replacement [19] and 7.1
for rheumatoid arthritis [20]. However, extrapolating findings
from other clinical populations is inappropriate [18, 19]. We
are not aware of any studies that have attempted to identify
the clinically relevant MCID for children.
In this study, we used three methods to define the
MCID of the SF-36-PFS in paediatric CFS/ME, a relatively
common (prevalence 0.4–2.4% [21–24]) and disabling
condition [25, 26]. We used the distribution method, the
anchor method, and a qualitative method.
Methods
The SF-36-PFS
The SF-36 is the most widely used general health-status
measure [27]. It includes eight scales, including the phys-
ical subscale which captures functional impairment. The
SF-36-PFS has 10 items and scoring ranges from 0 to 100,
with higher scores indicating better physical function. This
subscales asks respondents how limited they are (“a lot”,
“a little”, “not at all”) on everyday activities (e.g. “Bathing
or dressing yourself”). The SF-36 has been shown to be re-
liable and valid with acceptable internal consistency coeffi-
cients and differentiate psychiatric patients, patients with
minor conditions and chronic diseases [28].
Anchor method and distribution methods
Participants
We analysed routinely-collected data from a specialist paedi-
atric CFS/ME service in South-West England. Participants
completed the measures on paper forms which were
returned to the clinical team by hand at assessment and by
Table 1 A summary of the advantages and disadvantage of distribution, anchor and qualitative methods
Advantages Disadvantages
Distribution
method
• Distribution methods are based on statistical models [3].
• The value of 0.5 SD corresponds to the MCID across a
variety of studies [4].
• Guidelines for the interpretation of effect size are somewhat arbitrary.
• This statistical approach does not consider the core concept of the
MCID; the clinical importance [8].
• These methods are sample-specific; findings will vary on the sample
size and distribution that the SD is based on [38].
Anchor
method
• Anchor methods have the advantage of being
more clearly understood because change scores are
related to a clearly understood clinical observation [39].
• Global assessment scales are sensitive to change [40].
• Determining the cut-off on the anchor scale is often an arbitrary
decision [7].
• Global assessment scales may not always be valid. For example,
they can be susceptible to recall bias [41].
Qualitative
methods
• Gathering the views and experiences of patients provides
clinical relevance to the MCID.
• Qualitative data provides richer information from the
participants perspective which cannot be elicited through
standardized measures [8].
• Can lack the precision needed to determine a numerical marker
of MCID [8].
• Often includes smaller sample sizes, which can introduce issues
with generalisability [42].
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post at follow- up appointments. These included the
SF-36-PFS [9] collected at baseline and 6-month follow-up
and the Clinical Global Impression (CGI) scale collected at
6 month follow-up. The CGI consists of one item: “Overall,
how much have you changed since you first came to the
service?”, and is scored from 1 to 7, with 1 indicating “Very
much better”, 2 “Much better”, 3 “A little better”, 4 “No
change”, 5 “A little worse”, 6 “Much worse”, 7 “Very much
worse”.
Analyses
Distribution method Half of the standard deviation of
the baseline SF-36-PFS score at assessment was used to
calculate the MCID [4].
Anchor method We calculated the mean difference
(and 95% CI) between baseline and 6-month follow-up
scores for each level of response on the CGI.
Qualitative methods
Data were used from a larger qualitative study exploring
how “recovery” should be measured in paediatric CFS/ME,
and what improvement in fatigue and disability are import-
ant to young people and their parents. The participants
from this study were young people with CFS/ME and their
families, recruited from the Royal United Hospitals, Bath
Specialist Paediatric CFS/ME service. This service provides
assessment and treatment to over 400 children/adolescents
with CFS/ME annually. Young people were eligible if they
were: diagnosed with CFS/ME using NICE guidelines [29],
mild to moderately affected (not housebound) and aged be-
tween 12 and 17 years.
Qualitative interviews procedure
A section of the semi-structured topic guide (lasting 30–
45 min) included questions on the MCID; young people
and their parent/carers were asked open-ended questions
designed to explore what they considered the smallest
change on each item of the SF-36-PFS to be subjectively
meaningful. During the semi-structured interview, chil-
dren were asked to complete the SF-36-PFS. Participants
were asked to mark each question twice: once for where
they would currently rate themselves and a second time to
show what they felt would be the smallest amount of
change for them to feel treatment had made a difference
which was worth having treatment for. Parents/carers
were also asked to complete this process; to mark their
child’s current health status and then provide a second
mark to indicate the smallest amount of change to feel like
treatment has made a difference for their child. See Add-
itional file 1 for the topic guide.
Most interviews were undertaken in the participant’s
own home, one interview was undertaken on hospital
premises to coincide with an appointment. Partici-
pants included those recently assessed in clinic and
those from a year ago to understand how the impact
changes with illness duration. Children and their par-
ent(s) were mostly interviewed separately except in 4
out of 21 interviews a parent was present in the
room at the time of the child’s interview. The tran-
script section regarding MCID was not available for 1
child and 3 parents.
Each interview was audio recorded, transcribed, anon-
ymised and imported into NVivo. Two researchers ana-
lysed the transcripts using thematic analysis [30].
Results
Quantitative results
Six-month follow-up data were available for 198 chil-
dren, representing 26.9% (198/737) of children for whom
baseline data were available. Participants were aged be-
tween six and 17 years, with a mean age of 14 (SD 2.3).
Most were female (74%, 146/198) and 95% (185/195)
gave their ethnicity as “White British”. Mean (SD) base-
line and 6-month follow-up SF-36-PFS scores were 51.5
(21.4) and 65.3 (25.0), respectively.
Distribution method
Half the standard deviation of the baseline SF-36-PFS
scores is 10.7 (half of baseline SD of 21.4, N = 198) with
95% CI (9.7 to 11.9).
Anchor method
We used the CGI as the Anchor and analysed change in
SF-36-PFS from baseline to 6-month follow-up for each
response on the CGI. Table 2 displays the mean differ-
ence on the SF-36-PFS from baseline to 6-months
follow-up for each level of the CGI. “A little better” on
the CGI equates to a difference of 8.8 (95% CI 3.9 to
13.7, n = 67/198).
Qualitative results
Twenty-one children with CFS/ME participated: 16 fe-
males (76.2%) with a mean age of 14.4 years. Twenty
mothers and two fathers were also interviewed.
Eighteen out of 21 of the participants’ and their
parents/carers went through the SF-36-PFS during the
interview. At interview, one child had recovered and
did not take part. Two copies of the SF-36-PFS were
unavailable for analyses. On average, parents/ carers
rated their child as less disabled (median = 50), in
comparisons to the young person’s rating (median =
37.5). The distribution of change was highly skewed.
The median minimal improvement in the SF-36-PFS
was 10.
A number of participants had difficulty understanding
the concept of MCID and the purpose of the exercise.
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Eight children required clarification or further explanation
before they could complete the exercise due to confusion
about terms used or what was being asked of them. Mean-
while, parents were in general more receptive, giving lon-
ger, more detailed responses.
“Cause it’s small things”
During discussions, participants emphasised the import-
ance of basic mobility as a marker of meaningful im-
provement. Participants typically felt walking (100 yards
or half a mile) and climbing one flight of stairs was im-
portant as this level of mobility was seen as necessary
for the basic and essential daily tasks like being able to
move around their own home.
“Yeah, I’ve got, erm, my bedroom upstairs and my
brother’s bedroom is up-upstairs… So you’ve got to go
up those stairs” (Child).
Parents and children talked about how small changes
were important
“If like the climbing several flights of stairs went not limited
at all, would be a good, quite small change” (Child)
Participants perceived meaningful improvement as
that which enabled them to carry out routine basic daily
activities related to roles and relationships valuable to
them, with emphasis often being placed on involvement
in family and social activities:
“So you can help around the house and, and do things
with people.” (Child).
Participants commonly expressed a desire to be able
to carry out these activities without experiencing phys-
ical discomfort such as pain.
“Being able to lift and carry stuff, and not ache
afterwards.” (Child).
Accepting some level of limitation (in vigorous activity
and walking long distances)
Participants talked about acceptance of some level of
limitation. This was particularly true for the domain of
vigorous activity. Although some participants would like
to participate in exercise, they did not see this as an es-
sential marker of improvement.
“That’s it really, I mean I’m happy to just sort of get
on with it if it’s a little bit limited, I can just deal with
it” (Child).
“‘Cause, I mean, you don’t have to run, that’s not
really a big thing.” (Child).
Participants did not need complete recovery in walking
more than a mile and vigorous activities, as this was
seen as more of a luxury than a necessity of daily func-
tioning. Younger children talked more about wanting to
return to more vigorous activities such as sports. This
may be because P.E and afterschool clubs are important
opportunities for social interaction for young children.
One participant did state that vigorous activity was im-
portant. They felt that their condition had caused weight
gain and that being able to vigorous activity could be a
way to manage this.
Limitation of the SF-36-PFS and the MCID interview
The interviews revealed the limited scope of the
SF-36-PFS questions. The SF-36-PFS asks about specific
activities but not all aspects of SF-36-PFS were relevant
to participants and in some cases, the relevance changed
from day to day:
“But yeah I think some of the things on here I’ve never
really had a problem with doing anyway, like bathing,
undressing myself never really has been a problem.
Bending or stopping like there’s never really been a
problem with that, like I’ve aches and pains but it’s never
stopped me from doing any of those, so yeah.” (Child).
Table 2 Mean change in SF-36-PFS scores from baseline to 6-month follow-up for each level of the CGI response
Clinical Global Impression
at 6 months’ follow-up
SF-36-PFS change between baseline and 6-months’ follow-up
Median (IQR) Mean (95% CI) SD n
Very much better 30 (20, 40) 33.1 (25.1, 41.0) 19.3 25
Much better 20 (5, 35) 20.1 (14.8, 25.5) 22.3 69
A little better 10 (−5, 20) 8.8 (3.9, 13.7) 20.1 67
No change 0 (−12, 15) −0.9 (−11.9, 10.1) 18.2 13
A little worse 7 (−10, 10) 3.8 (−9.9, 17.6) 22.7 13
Much worse −15 (−20, 5) −6.8 (− 20.5, 6.9) 17.8 9
Very much worse −25 (−40, −10) −25.0 (− 215.6, 165.6) 21.2 2
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“…it’s so variable day to day that you can’t pigeonhole
it in those little things like, do you know what I mean?
I don’t know if that’s the answer you want, but that is
the answer I feel is right…” (Parent).
Triangulating the findings
To triangulate the findings, we calculated the mean of
the scores [31] from the distribution method (10.90), the
anchor method (8.99) and the qualitative interviews (10)
to determine an MCID of 10.
Discussion
This is the first study to calculate the minimally clinically
important difference (MCID) of the SF-36-PFS for young
people with CFS/ME. It is also the first study to calculate
the MCID of the SF-36-PFS for children with a chronic
disease. We used three different methods, which sug-
gested that a MCID of 10 was appropriate (distribution
method = 10.7, anchor method = 8.8 and qualitative inter-
views = 10). The qualitative data enriches this finding, in-
dicating that small changes in physical function can lead
to important improvements in valued social and family
function. Patients and parents are positive about improve-
ment even in the presence of persisting symptoms.
Strengths and limitations
The main strength is that we used three different methods
to define the MCID of the SF-36-PFS in this patient group,
which increases our confidence in the result. Using mul-
tiple quantitative methods increases confidence in the ac-
curacy of the findings, and qualitative methods ensures the
MCID is clinically relevant. The sample sizes for the statis-
tical methods were reasonably large. The overall propor-
tion of children who provided 6-month follow-up data was
relatively low, but we would not expect this to bias the re-
lationship between follow-up SF-36-PFS scores and CGI
levels or to yield a wider or narrower standard deviation
for baseline SF-36-PFS scores.
Qualitative interviews included both young people and
their parents, because children and parents do not necessar-
ily share similar views about the impact of illness [32]. All
participants received their diagnosis from a large specialist
paediatric CFS/ME service, and our sample was representa-
tive of patients attending the service. Since a number of in-
terviews were conducted with the child’s parent(s) present, it
is possible that parents may have influenced the child’s an-
swer. Participants were recruited from one specialist service,
the results may not be generalisable to other services. We
did not interview children who were under the age of 12, se-
verely affected (house or bed bound) and therefore we can-
not extrapolate results to these patient groups.
We only looked at the MCID of one scale, the
SF-36-PFS, which captures physical disability. This study
has not considered MCID for scales that capture other as-
pects of the illness, such as symptoms of fatigue and pain.
However, the SF-36-PFS in an important measure as
young people with CFS/ME feel that a lack of social par-
ticipation and low mood is secondary to the symptoms
and physical disability they experience [33, 34]. Further, it
has been used in studies for paediatric CFS/ME in the UK,
Australia and the Netherlands [14, 17, 35–37].
Context of previous literature
We were unable to compare our results with other paediat-
ric studies, because we could not find published data on
the MCID for the SF-36-PFS. However, our results are con-
sistent with a Delphi consensus, which suggested an MCID
of 10 for asthma and heart disease [18]. The range in adult
studies investigating the MCID in different conditions with
different methodology is wide (3.25–20.40) [18–20].
Our qualitative findings suggested that small changes are
important because they enabled greater function, even with
the persistence of symptoms. This is consistent with the
views of patients with COPD who acknowledged that a large
improvement on the Breathlessness Diary (BD) measure
may not be a realistic goal of treatment, and reported that a
1-point step-change would be considered “dramatic” [8].
Conclusions
An MCID of 10 should be used in paediatric CFS/ME
treatment trials and observational studies for the
SF-36-PFS. Clinicians should remember that relatively
small changes in physical function are worthwhile for
patients and their families as this can lead to a reduction
in social and family limitations.
Further research is needed to define the MCID on
measures which capture other aspects of CFS/ME, such
as fatigue and pain measures.
Additional file
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ME (PDF 65 kb)
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